Crinetics Pharmaceuticals (CRNX) Operating Leases (2019 - 2026)

Crinetics Pharmaceuticals' Operating Leases history runs 8 years deep, the most recent figure standing at $41.3 million for Q1 2026.

• In Q1 2026, Operating Leases fell 5.96% year-over-year to $41.3 million; the TTM figure through Mar 2026 stood at $41.3 million (down 5.96% YoY), while the FY2025 annual figure was $42.1 million, down 5.65% from the prior year.
• Operating Leases was $41.3 million for Q1 2026 at Crinetics Pharmaceuticals, down from $42.1 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $49.1 million in Q3 2025 to a low of $1.5 million in Q2 2023.
• Historically, Operating Leases has averaged $30.0 million across 5 years, with a median of $43.3 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Operating Leases sank 43.24% in 2023, then surged 3050.62% in 2024.
• A 5-year view of Operating Leases shows it stood at $2.0 million in 2022, then soared by 2249.56% to $47.6 million in 2023, then slipped by 6.28% to $44.6 million in 2024, then dropped by 5.65% to $42.1 million in 2025, then retreated by 1.74% to $41.3 million in 2026.
• The last three Operating Leases figures came in at $41.3 million (Q1 2026), $42.1 million (Q4 2025), and $49.1 million (Q3 2025), per Business Quant data.